Edmund M. Harrington

发表

Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data.

John A. Tallarico, A. Bender, J. Jenkins, 2009, Journal of proteome research.

Examining the influence of specificity ligands and ATP-competitive ligands on the overall effectiveness of bivalent kinase inhibitors

M. Schirle, Edmund M. Harrington, J. Thomas, 2016, Proteome Science.

loading compartment of human plasmacytoid dendritic cells Small molecule Toll-like receptor 7 agonists localize to the MHC class II

J. Tallarico, Edmund M. Harrington, I. Cornella-Taracido, 2011 .

Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells.

J. Tallarico, Edmund M. Harrington, I. Cornella-Taracido, 2011, Blood.

Cysteine and methionine linked by carbon pseudopeptides inhibit farnesyl transferase

Edmund M. Harrington, A. García, K. Ackermann, 1994 .

Bile acid analogues are activators of pyrin inflammasome

Stephen M. Canham, Edmund M. Harrington, S. Menon, 2019, The Journal of Biological Chemistry.

Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells

Gregory McAllister, Sven Schuierer, Gregory R. Hoffman, 2017, Scientific Reports.

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

Edmund M. Harrington, W. Ni, W. Forrester, 2022, Blood Cancer Journal.

Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).

Jian Wang, G. Bemis, F. Salituro, 2008, Bioorganic & medicinal chemistry letters.

Detecting S-adenosyl-L-methionine-induced conformational change of a histone methyltransferase using a homogeneous time-resolved fluorescence-based binding assay.

Mathias Frederiksen, P. Atadja, Edmund M. Harrington, 2012, Analytical Biochemistry.

Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo

John A. Tallarico, M. Schirle, Christopher J. Wilson, 2014, Nature Cell Biology.

Previously Uncharacterized Vacuolar-type ATPase Binding Site Discovered from Structurally Similar Compounds with Distinct Mechanisms of Action.

John A. Tallarico, M. Schirle, Xuewen Pan, 2018, ACS chemical biology.

Conversion of a Single Polypharmacological Agent into Selective Bivalent Inhibitors of Intracellular Kinase Activity.

Dustin J Maly, M. Schirle, Edmund M. Harrington, 2016, ACS chemical biology.

Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo.

P. Finan, M. Glick, P. Furet, 2016, ACS medicinal chemistry letters.

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.

F. Salituro, Hui-Sheng Huang, Edmund M. Harrington, 2015, Journal of medicinal chemistry.

Kinase inhibitor profiling using chemoproteomics.

David Schwalb, John A. Tallarico, M. Schirle, 2012, Methods in molecular biology.

Chemoproteomics Enabled Discovery of Selective Probes for NuA4 Factor BRD8

M. Schirle, Edmund M. Harrington, W. Forrester, 2021, bioRxiv.

The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.

Huai Gao, Yow-Ming Wang, Yow-Ming C Wang, 2011, ACS medicinal chemistry letters.

Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.

G. Bemis, F. Salituro, Edmund M. Harrington, 2009, Bioorganic & medicinal chemistry letters.

Examining the influence of specificity ligands and ATP-competitive ligands on the overall effectiveness of bivalent kinase inhibitors

M. Schirle, Edmund M. Harrington, J. Thomas, 2017, Proteome Science.

Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.

G. Bemis, F. Salituro, Edmund M. Harrington, 2009, Bioorganic & medicinal chemistry letters.